Anti-Anginal and Beta-Adrenoceptor Blocking Drugs

The 1983 document details the effects, side effects, and interactions of beta-adrenoceptor blocking drugs (beta-blockers) and other anti-anginal medications. It reports central nervous system side effects like psychosis and depression from propranolol, which improve with reduced dosage or discontinuation, and notes propranolol's potential to increase serum levels of chlorpromazine and cause visual disturbances. Beta-blockers may initially impair driving performance, but tolerance can develop. Cardiovascular effects include metoprolol's use in congestive cardiomyopathy, acebutolol's negative impact on exercise tolerance, and the risk of beta-blockers worsening ischemic heart failure. The document also discusses the hypotensive effects of beta-blockers, the risk of severe hypotension, and their use in autonomic nervous system degeneration. It covers cardiac arrhythmias, including sotalol's rare side effect of torsade de pointes tachycardia, and the cautious use of beta-blockers in patients over 70-75 years old and those with contraindications after myocardial infarction. The document mentions a case of alopecia associated with metoprolol that improved after drug discontinuation and highlights the need for individualized treatment and careful monitoring, especially in patients with diabetes, respiratory diseases, and during pregnancy. It also discusses the exacerbation of allergic reactions by beta-blockers, the preference for beta₁-selective drugs in atopic patients, and the potential link between beta-blockers and conditions like sclerosing peritonitis and retroperitoneal fibrosis. Newer beta-blockers like nadolol and penbutolol are mentioned, with nadolol having no reported autoimmune disorders and penbutolol showing ocular side effects. Overdosage symptoms and drug interactions are also covered. Additionally, the document reviews side effects of nitrate derivatives and calcium antagonists, with nifedipine and verapamil causing side effects like flushing and ankle edema, and the need for caution with verapamil in Wolff-Parkinson-White syndrome patients. Lastly, it discusses the effects of verapamil and diltiazem on glucose metabolism, prenylamine's association with ventricular tachycardia, perhexiline's severe side effects including hypoglycemia and hepatocellular injury, and the need for more data on the safety and effects of these drugs, particularly in diabetic patients.